JP2015531371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015531371A5 JP2015531371A5 JP2015534463A JP2015534463A JP2015531371A5 JP 2015531371 A5 JP2015531371 A5 JP 2015531371A5 JP 2015534463 A JP2015534463 A JP 2015534463A JP 2015534463 A JP2015534463 A JP 2015534463A JP 2015531371 A5 JP2015531371 A5 JP 2015531371A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- heteroaryl
- aryl
- cycloalkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- -1 CF 3 Inorganic materials 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 claims 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000004221 bone function Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261707661P | 2012-09-28 | 2012-09-28 | |
| US61/707,661 | 2012-09-28 | ||
| PCT/US2013/032588 WO2014051698A1 (en) | 2012-09-28 | 2013-03-15 | Fused heterocyclic compounds as selective bmp inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015531371A JP2015531371A (ja) | 2015-11-02 |
| JP2015531371A5 true JP2015531371A5 (OSRAM) | 2016-05-12 |
| JP6430383B2 JP6430383B2 (ja) | 2018-11-28 |
Family
ID=50388847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015534463A Expired - Fee Related JP6430383B2 (ja) | 2012-09-28 | 2013-03-15 | 選択的ｂｍｐ阻害剤としての縮合複素環化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9738636B2 (OSRAM) |
| EP (1) | EP2900238B1 (OSRAM) |
| JP (1) | JP6430383B2 (OSRAM) |
| KR (1) | KR102092988B1 (OSRAM) |
| CN (1) | CN104768548B (OSRAM) |
| AU (1) | AU2013324396B2 (OSRAM) |
| BR (1) | BR112015007136A2 (OSRAM) |
| CA (1) | CA2886187C (OSRAM) |
| DK (1) | DK2900238T3 (OSRAM) |
| ES (1) | ES2660051T3 (OSRAM) |
| SG (1) | SG11201503299YA (OSRAM) |
| WO (1) | WO2014051698A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5986570B2 (ja) | 2010-09-01 | 2016-09-06 | トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 筋修復および再生のための組成物および方法 |
| DK3105226T3 (da) | 2014-02-13 | 2019-10-14 | Incyte Corp | Cyclopropylaminer som lsd1-inhibitorer |
| PT3105218T (pt) | 2014-02-13 | 2019-12-05 | Incyte Corp | Ciclopropilaminas como inibidores de lsd1 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| EP3626720A1 (en) | 2015-04-03 | 2020-03-25 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| WO2017024406A1 (en) | 2015-08-11 | 2017-02-16 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| EP3334717B1 (en) | 2015-08-11 | 2020-07-01 | Neomed Institute | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals |
| KR102710120B1 (ko) | 2015-08-12 | 2024-09-27 | 인사이트 홀딩스 코포레이션 | Lsd1 저해제의 염 |
| WO2017024412A1 (en) | 2015-08-12 | 2017-02-16 | Neomed Institute | Substituted benzimidazoles, their preparation and their use as pharmaceuticals |
| US10501459B2 (en) | 2015-10-21 | 2019-12-10 | Neomed Institute | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors |
| WO2017127930A1 (en) * | 2016-01-28 | 2017-08-03 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals |
| MY200642A (en) | 2016-06-08 | 2024-01-08 | Clementia Pharmaceuticals Inc | Method for treating heterotopic ossification |
| DK3971177T3 (da) | 2016-07-20 | 2024-07-15 | Novartis Ag | Aminopyridin-derivater og anvendelse deraf som selektive ALK-2-inhibitorer |
| JP2019533643A (ja) * | 2016-09-14 | 2019-11-21 | ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ | Ｂｍｐシグナル伝達の阻害、その化合物、組成物および使用 |
| EP3570843A1 (en) * | 2017-01-18 | 2019-11-27 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
| US10745400B2 (en) | 2018-03-14 | 2020-08-18 | Vanderbuilt University | Inhibition of BMP signaling, compounds, compositions and uses thereof |
| CN110496127A (zh) * | 2018-05-17 | 2019-11-26 | 中国科学院上海生命科学研究院 | 一种热休克因子1的抑制剂、其制备方法和应用 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| MA54551A (fr) * | 2018-12-20 | 2021-10-27 | Incyte Corp | Composés d'imidazopyridazine et d'imidazopyridine utilisés en tant qu'inhibiteurs de la kinase 2 de type récepteur de l'activine |
| KR20220088699A (ko) | 2019-09-27 | 2022-06-28 | 디스크 메디슨, 인크. | 골수섬유증 및 관련 상태의 치료 방법 |
| CN115038443A (zh) | 2019-11-22 | 2022-09-09 | 因西特公司 | 包含alk2抑制剂和jak2抑制剂的组合疗法 |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2021257532A1 (en) | 2020-06-16 | 2021-12-23 | Incyte Corporation | Alk2 inhibitors for the treatment of anemia |
| WO2024205336A1 (ko) * | 2023-03-30 | 2024-10-03 | 에이치엘비생명과학알앤디 주식회사 | 튜블린 저해 활성을 갖는 약학적 조성물 |
| WO2024239187A1 (zh) * | 2023-05-22 | 2024-11-28 | 睿健医药科技(苏州)有限公司 | Bmpr1b抑制剂在诱导发育中的应用、诱导培养基 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2562071B1 (fr) | 1984-03-30 | 1986-12-19 | Sanofi Sa | Triazolo(4,3-b)pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| GB9927687D0 (en) * | 1999-11-23 | 2000-01-19 | Merck Sharp & Dohme | Therapeutic agents |
| JP4747396B2 (ja) | 2000-05-17 | 2011-08-17 | 日立化成工業株式会社 | 接着剤組成物、それを用いた回路端子の接続方法及び回路端子の接続構造 |
| ATE416175T1 (de) | 2001-02-20 | 2008-12-15 | Astrazeneca Ab | 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen |
| EP1503757B1 (en) | 2002-05-02 | 2007-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
| AU2007307031B2 (en) * | 2006-10-11 | 2011-11-24 | Amgen Inc. | Imidazo- and triazolo-pyridine compounds and methods of use therof |
| HRP20151398T1 (hr) | 2006-12-22 | 2016-02-12 | Astex Therapeutics Limited | Tricikliäśni derivati amina kao inhibitori protein tirozin kinaze |
| CN101679408B (zh) * | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | 作为fgfr抑制剂的双环杂环化合物 |
| ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| CA2682231A1 (en) | 2007-03-28 | 2008-10-09 | Array Biopharma Inc. | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
| UA101611C2 (ru) | 2007-04-03 | 2013-04-25 | Аррей Байофарма Инк. | СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ |
| JP2010531875A (ja) | 2007-06-26 | 2010-09-30 | ギリード・サイエンシズ・インコーポレーテッド | イミダゾピリジニルチアゾリルヒストンデアセチラーゼ阻害剤 |
| WO2009013335A1 (en) | 2007-07-26 | 2009-01-29 | Novartis Ag | Organic compounds |
| MX2010004244A (es) * | 2007-10-17 | 2010-04-30 | Novartis Ag | Derivados de imidazo [i,2-a]-piridina utiles como inhibidores de cinasa tipo activina (alk). |
| EP2265603B1 (en) | 2008-03-13 | 2014-05-07 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| WO2009157423A1 (ja) * | 2008-06-24 | 2009-12-30 | 財団法人乙卯研究所 | 縮合環を有するオキサゾリジノン誘導体 |
| US8592425B2 (en) * | 2009-01-16 | 2013-11-26 | Merck Sharp & Dohme Corp. | Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors |
| MX2011009796A (es) | 2009-03-20 | 2011-12-14 | Amgen Inc | Inhibidores de la cinasa pi3. |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| EP2563792B1 (en) * | 2010-04-28 | 2014-08-27 | Bristol-Myers Squibb Company | Imidazopyridazinyl compounds and their uses for cancer |
| MX2012012145A (es) * | 2010-04-28 | 2012-11-21 | Daiichi Sankyo Co Ltd | Compuestos [5, 6] heterociclico. |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| WO2013016452A2 (en) | 2011-07-25 | 2013-01-31 | Vanderbilt University | Cancer treatment using bmp inhibitor |
| EP2615151A1 (en) | 2011-12-23 | 2013-07-17 | Services Pétroliers Schlumberger | Compositions and methods for well cementing |
| WO2014138088A1 (en) | 2013-03-04 | 2014-09-12 | The Brigham And Women's Hospital, Inc. | Bmp inhibitors and methods of use thereof |
| US9682983B2 (en) | 2013-03-14 | 2017-06-20 | The Brigham And Women's Hospital, Inc. | BMP inhibitors and methods of use thereof |
-
2013
- 2013-03-15 CA CA2886187A patent/CA2886187C/en not_active Expired - Fee Related
- 2013-03-15 SG SG11201503299YA patent/SG11201503299YA/en unknown
- 2013-03-15 US US14/432,472 patent/US9738636B2/en not_active Expired - Fee Related
- 2013-03-15 DK DK13840866.1T patent/DK2900238T3/en active
- 2013-03-15 EP EP13840866.1A patent/EP2900238B1/en not_active Not-in-force
- 2013-03-15 BR BR112015007136A patent/BR112015007136A2/pt not_active IP Right Cessation
- 2013-03-15 WO PCT/US2013/032588 patent/WO2014051698A1/en not_active Ceased
- 2013-03-15 ES ES13840866.1T patent/ES2660051T3/es active Active
- 2013-03-15 CN CN201380058849.8A patent/CN104768548B/zh not_active Expired - Fee Related
- 2013-03-15 KR KR1020157011027A patent/KR102092988B1/ko not_active Expired - Fee Related
- 2013-03-15 AU AU2013324396A patent/AU2013324396B2/en not_active Ceased
- 2013-03-15 JP JP2015534463A patent/JP6430383B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-17 US US15/652,100 patent/US10196392B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015531371A5 (OSRAM) | ||
| JP2019519467A5 (OSRAM) | ||
| JP2017538677A5 (OSRAM) | ||
| JP2016531126A5 (OSRAM) | ||
| RU2021115958A (ru) | Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы | |
| JP2017537080A5 (OSRAM) | ||
| JP2016505614A5 (OSRAM) | ||
| JP2010511721A5 (OSRAM) | ||
| JP2014508811A5 (OSRAM) | ||
| JP2013537203A5 (OSRAM) | ||
| EP2746281A3 (de) | 7-Azaindolderivate | |
| SI2970216T1 (en) | Biaryl-amide compounds as kinase inhibitors | |
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| JP2012515776A5 (OSRAM) | ||
| AR089527A1 (es) | Inhibidores de bromodominios | |
| JP2009529540A5 (OSRAM) | ||
| JP2018523761A5 (OSRAM) | ||
| JP2014029971A5 (ja) | 有機化合物 | |
| JP2013540755A5 (OSRAM) | ||
| JP2012006912A5 (ja) | トリアゾール誘導体 | |
| JP2016526540A5 (OSRAM) | ||
| JP2012140436A5 (ja) | 物質 | |
| JP2014524441A5 (OSRAM) | ||
| JP2015512398A5 (OSRAM) | ||
| JP2016503797A5 (OSRAM) |